
Prevalence Rate of Acute MI: 2023 female baseline 0.0025 outreach 100 outreach 50 0.0020 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 90_to_94 95_plus 50_to_54 35_to_39 40_to_44 45_to_49 60_to_64 65_to_69 85_to_89 25_to_29 55_to_59

Prevalence Rate of Acute MI: 2024 female 0.0025 baseline outreach 100 outreach 50 0.0020 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 45_to_49 50_to_54 60_to_64 65_to_69 25_to_29 30_to_34 35_to_39 40_to_44 85_to_89 90_to_94 55_to_59



Prevalence Rate of Acute MI: 2026 female 0.00200 baseline outreach 100 0.00175 outreach 50 0.00150 0.00125 0.00100 0.00075 0.00050 0.00025 0.00000 95_plus 65_to_69 70_to_74 75_to_79 35_to_39 40_to_44 45_to_49 50_to_54 55_to_59 60_to_64 80_to_84 85_to_89 90_to_94 25_to_29 30_to_34

Prevalence Rate of Acute MI: 2027 female baseline 0.0020 outreach 100 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 50_to_54 60_to_64 25_to_29 35_to_39 40_to_44 45_to_49 65_to_69 85_to_89 90_to_94 55_to_59


Prevalence Rate of Acute MI: 2028 female baseline 0.0020 outreach 100 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 45_to_49 50_to_54 60_to_64 25_to_29 35_to_39 40_to_44 55_to_59 65_to_69 85_to_89 90_to_94


Prevalence Rate of Acute MI: 2029 female baseline 0.0020 outreach 100 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 45_to_49 50_to_54 60_to_64 25_to_29 35_to_39 40_to_44 55_to_59 65_to_69 85_to_89 90_to_94


Prevalence Rate of Acute MI: 2030 female baseline 0.0020 outreach 100 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 50_to_54 60_to_64 65_to_69 25_to_29 35_to_39 40_to_44 45_to_49 85_to_89 90_to_94 55_to_59


Prevalence Rate of Acute MI: 2031 female baseline outreach 100 0.0020 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 45_to_49 50_to_54 60_to_64 25_to_29 30_to_34 35_to_39 40_to_44 65_to_69 85_to_89 90_to_94 55_to_59

Prevalence Rate of Acute MI: 2032 female baseline 0.0020 outreach 100 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 45_to_49 50_to_54 60_to_64 25_to_29 35_to_39 40_to_44 65_to_69 85_to_89 90_to_94 55_to_59











Prevalence Rate of Acute MI: 2037 female baseline outreach 100 0.0020 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 45_to_49 50_to_54 60_to_64 25_to_29 35_to_39 40_to_44 65_to_69 85_to_89 90_to_94 55_to_59





Prevalence Rate of Acute MI: 2040 female baseline 0.0020 outreach 100 outreach 50 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 45_to_49 50_to_54 60_to_64 65_to_69 25_to_29 30_to_34 35_to_39 40_to_44 55_to_59 85_to_89 90_to_94

Prevalence Rate of Acute MI: 2023 male baseline 0.004 outreach 100 outreach 50 0.003 0.002 0.001 0.000 40_to_44 85_to_89 45_to_49 50_to_54 95_plus 65_to_69 70_to_74 75_to_79 80_to_84 35_to_39 55_to_59 60_to_64 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2024 male baseline 0.0040 outreach 100 0.0035 outreach 50 0.0030 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 50_to_54 80_to_84 95_plus 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 70_to_74 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2025 male baseline 0.004 outreach 100 outreach 50 0.003 0.002 0.001 0.000 45_to_49 80_to_84 85_to_89 50_to_54 95_plus 65_to_69 70_to_74 75_to_79 35_to_39 40_to_44 55_to_59 60_to_64 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2026 male baseline 0.0030 outreach 100 outreach 50 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 50_to_54 60_to_64 90_to_94 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 25_to_29

Prevalence Rate of Acute MI: 2027 male 0.0040 baseline outreach 100 0.0035 outreach 50 0.0030 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 70_to_74 80_to_84 95_plus 50_to_54 60_to_64 75_to_79 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2028 male baseline 0.004 outreach 100 outreach 50 0.003 0.002 0.001 0.000 85_to_89 45_to_49 50_to_54 80_to_84 95_plus 65_to_69 70_to_74 75_to_79 35_to_39 40_to_44 55_to_59 60_to_64 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2029 male 0.0040 baseline outreach 100 0.0035 outreach 50 0.0030 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 50_to_54 70_to_74 75_to_79 80_to_84 95_plus 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2030 male baseline 0.004 outreach 100 outreach 50 0.003 0.002 0.001 0.000 80_to_84 85_to_89 45_to_49 50_to_54 95_plus 65_to_69 70_to_74 35_to_39 40_to_44 55_to_59 60_to_64 75_to_79 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2031 male 0.0035 baseline outreach 100 0.0030 outreach 50 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 45_to_49 70_to_74 80_to_84 95_plus 50_to_54 60_to_64 30_to_34 35_to_39 40_to_44 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2032 male 0.0030 baseline outreach 100 0.0025 outreach 50 0.0020 0.0015 0.0010 0.0005 0.0000 70_to_74 75_to_79 80_to_84 95_plus 50_to_54 60_to_64 90_to_94 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 25_to_29

Prevalence Rate of Acute MI: 2033 male baseline 0.0040 outreach 100 0.0035 outreach 50 0.0030 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 50_to_54 70_to_74 80_to_84 95_plus 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2034 male 0.0035 baseline outreach 100 0.0030 outreach 50 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 50_to_54 70_to_74 80_to_84 95_plus 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2035 male 0.0035 baseline outreach 100 0.0030 outreach 50 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 50_to_54 70_to_74 80_to_84 95_plus 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2036 male 0.0035 baseline outreach 100 0.0030 outreach 50 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 50_to_54 70_to_74 80_to_84 95_plus 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2037 male 0.0040 baseline outreach 100 0.0035 outreach 50 0.0030 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 50_to_54 70_to_74 80_to_84 90_to_94 95_plus 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 25_to_29

Prevalence Rate of Acute MI: 2038 male 0.0040 baseline outreach 100 0.0035 outreach 50 0.0030 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 50_to_54 70_to_74 80_to_84 95_plus 60_to_64 75_to_79 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2039 male 0.0035 baseline outreach 100 0.0030 outreach 50 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 80_to_84 95_plus 50_to_54 60_to_64 70_to_74 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 90_to_94 25_to_29

Prevalence Rate of Acute MI: 2040 male baseline 0.0035 outreach 100 outreach 50 0.0030 0.0025 0.0020 0.0015 0.0010 0.0005 0.0000 75_to_79 · 70_to_74 80_to_84 95_plus 50_to_54 60_to_64 90_to_94 30_to_34 35_to_39 40_to_44 45_to_49 55_to_59 65_to_69 85_to_89 25_to_29